相关实验视频

Updated: Jan 13, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

基于结构的混合化策略揭示了SirReal型Sirt2抑制剂的主要功效增强

Matthias Frei¹, Ricky Wirawan¹, Thomas Wein¹

¹Department of Pharmacy, Center for Drug Research, Ludwig-Maximilians University, Butenandtstr. 5-13, 81377 Munich, Germany.

International journal of molecular sciences

|October 29, 2025

概括

研究人员开发了RW-93,一种强效和选择性的Sirt2抑制剂,为帕金森氏症和阿尔茨海默氏症等神经退行性疾病提供了新的表观遗传策略. 这一发现推动了Sirt2抑制剂的开发,用于治疗目前无法治愈的疾病.

科学领域:

生物化学生物化学
神经科学是一个神经科学.
药用化学医学化学

背景情况:

赛尔图因2 (Sirt2) 抑制剂是治疗神经退行性疾病的关键表观遗传标.
目前的Sirt2抑制剂具有局限性,需要开发更强效和选择性的化合物.

研究的目的:

设计和合成新型,高强度和亚型选择性Sirt2抑制剂.
探索下一代Sirt2抑制剂的结构-活性关系 (SAR).

主要方法:

基于结构的药物设计,使用分子对接和MM/GBSA验证.
结构混合化策略,以创建一系列新的Sirt2抑制剂.

主要成果:

鉴定RW-93,一种高强度的Sirt2抑制剂,IC50为16nM.
与现有的Sirt2抑制剂相比,RW-93显示出更高的效能和选择性.
这项研究成功地扩展了Sirt2抑制剂的SAR概况.

结论:

RW-93代表了Sirt2抑制剂开发的重大进展.
这些发现为进一步的药物化学努力在治疗神经退行性疾病方面提供了有希望的基础.
这项研究为未来的治疗策略提供了一种强大的低分子量Sirt2抑制剂.

关键词:

谢尔·里亚尔2先生这是一种Sirt2抑制剂.具有高度强效和选择性的Sirt2抑制剂.混合化战略的混合化策略.这是一种Sirtuin 2 抑制剂.结构优化结构优化结构活动关系结构活动关系

更多相关视频

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Published on: February 27, 2016

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...